Healthtech Solutions (OTC: HLTT) has signed a contract to acquire a wholly owned subsidiary, Healthtech Oncology Inc., which will subsequently own a 100% interest in Varian Biopharmaceuticals Inc., a precision oncology company. Varian Bio is developing novel therapeutics for the treatment of cancer, including a proprietary atypical protein kinase C iota (“aPKCi”) inhibitor. Varian Bio’ has two lead drug candidates: VAR-101 (“VAR-101”) and VAR-102 (“VAR-102”); both drug candidates are in the pre-clinical research stage of development. HLTT’s investment in Varian aligns with its commitment to acquire and invest in cutting-edge healthcare technological companies. Precision oncology, which is when researchers and health care professionals utilize DNA testing to identify genetic mutations of unique tumors, may provide more targeted treatment recommendations designed to fight specific tumor types. In the announcement, Varian Bio noted that it has the support of leading oncology physicians and scientific institutions both in the United States and globally. “Varian Bio is at the leading edge of cancer treatment technology and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman and CEO David Rubin in the press release. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field and we’re thrilled to be a part of it.”
To view the full press release, visit https://ibn.fm/wGFcD
About Healthtech Solutions Inc.
Healthtech Solutions, through its subsidiary Mediscan Inc., offers technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology has multiple applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.MyMediScan.com.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.